{"filing":{"accession_number":"0001193125-26-338019","cik":"0001582313","ticker":"XENE","company_name":"Xenon Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"xene-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526338019/xene-20260806.htm"},"events":[{"id":25628,"run_id":23259,"accession_number":"0001193125-26-338019","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Xenon Pharmaceuticals reported Q2 2026 financial results for the three and six months ended June 30, 2026, disclosing a net loss of $110.7M, R\u0026D expenses of $99.2M, G\u0026A expenses of $23.9M, other income of $11.8M, and a cash position of $1.245B, along with clinical development updates on its pipeline programs including azetukalner.","company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26511,"accession_number":"0001193125-26-338019","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard earnings release disclosing Xenon's financial results for Q2 2026 (three and six months ended June 30, 2026), filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) reports quarterly financial metrics including R\u0026D expenses ($99.2M), G\u0026A expenses ($23.9M), other income ($11.8M), and net loss ($110.7M), along with cash position ($1.245B) and business updates on clinical programs. This is material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:26.232708+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26512,"accession_number":"0001193125-26-338019","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure is accompanied by Exhibit 99.1, which is a press release titled \"Xenon Reports Q2 2026 Financial Results and Provides Business Update.\" The exhibit contains detailed quarterly financial results including R\u0026D expenses ($99.2M), G\u0026A expenses ($23.9M), net loss ($110.7M), and cash position ($1.245B), along with clinical development milestones for azetukalner and other pipeline programs. This is a standard earnings release disclosure for a biopharmaceutical company reporting quarterly results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:26.232708+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26511,"accession_number":"0001193125-26-338019","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard earnings release disclosing Xenon's financial results for Q2 2026 (three and six months ended June 30, 2026), filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) reports quarterly financial metrics including R\u0026D expenses ($99.2M), G\u0026A expenses ($23.9M), other income ($11.8M), and net loss ($110.7M), along with cash position ($1.245B) and business updates on clinical programs. This is material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:26.232708+00:00","company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","filing_date":"2026-08-06"},{"id":26512,"accession_number":"0001193125-26-338019","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure is accompanied by Exhibit 99.1, which is a press release titled \"Xenon Reports Q2 2026 Financial Results and Provides Business Update.\" The exhibit contains detailed quarterly financial results including R\u0026D expenses ($99.2M), G\u0026A expenses ($23.9M), net loss ($110.7M), and cash position ($1.245B), along with clinical development milestones for azetukalner and other pipeline programs. This is a standard earnings release disclosure for a biopharmaceutical company reporting quarterly results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:26.232708+00:00","company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","filing_date":"2026-08-06"}]}